This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Teladoc (TDOC) concluded the recent trading session at $10.66, signifying a +0.19% move from its prior day's close.
Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, Teladoc (TDOC) closed at $10.87, indicating a -1.9% shift from the previous trading day.
Elevance Health (ELV) Stock Jumps 6.1%: Will It Continue to Soar?
by Zacks Equity Research
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $11.15, denoting a -1.85% change from the preceding trading day.
Here is What to Know Beyond Why Teladoc Health, Inc. (TDOC) is a Trending Stock
by Zacks Equity Research
Teladoc (TDOC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Teladoc Health (TDOC) Q1 Loss Widens on Decline in Visits
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results suffer from weak contributions from the BetterHelp unit. Management expects U.S. Integrated Care Members of 92-94 million for 2024, up from the prior mentioned 90-92 million.
Teladoc (TDOC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of -4.26% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.
Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $13.14, marking a +0.08% move from the previous day.
Teladoc (TDOC) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $14.85, denoting a -1.66% change from the preceding trading day.
Here's Why Investors Should Hold Teladoc (TDOC) Stock Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Teladoc (TDOC) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Teladoc (TDOC) settling at $15.08, representing a +0.53% change from its previous close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Teladoc Health (TDOC) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Teladoc Health (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc (TDOC) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) reachead $15.12 at the closing of the latest trading day, reflecting no change compared to its last close.
Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $15.37, moving -1.41% from the previous trading session.
Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss
by Zacks Equity Research
Teladoc Health (TDOC) expands weight management capabilities by coming up with a tailored solution that aims to reduce obesity-related medical care expenses for members.
Teladoc (TDOC) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $14.58, marking a +1.32% move from the previous day.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) concluded the recent trading session at $15.08, signifying a -0.07% move from its prior day's close.
Teladoc Health (TDOC) Q4 Loss Narrows on Lower Expenses
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 results were aided by strong contributions from the Integrated Care unit and a decline in restructuring costs. Management targets adjusted EBITDA at a minimum of $425 million in 2025.
Teladoc (TDOC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Teladoc (TDOC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 22.73% and 1.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?